3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Imatinib Mesylate
6
Laparoscopy
3
Surgical Procedures, Operative
2
spartalizumab
1
ripretinib
1
regorafenib
1
ponatinib
1
famitinib
1
apixaban
1
anlotinib
1
Thoracic Surgery, Video-Assisted
1
TH 302
1
Surveys and Questionnaires
1
Surgical Tape
1
Sunitinib
1
Rivaroxaban
1
Oxaliplatin
1
Nivolumab
1
Liver Transplantation
1
Ipilimumab
1
Interviews as Topic
1
Endoscopic Mucosal Resection
1
Dasatinib
1
Dalteparin
1
Blood Specimen Collection
1
Biopsy
1
68Ga-NOTA-RM26
1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastrointestinal Stromal Tumors
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled